CSIMarket Company Name, Ticker, Industry, else..
 
Creative Medical Technology Holdings Inc   (NASDAQ: CELZ)
 
Price: $1.0600 $-0.02 -1.852%
Day's High: $1.0850000381469727 Week Perf: -6.19 %
Day's Low: $ 1.05 30 Day Perf: -11.67 %
Volume (M): 69,787 52 Wk High: $ 6.25
Volume (M$): $ 0 52 Wk Avg: $2.16
Open: $1.08 52 Wk Low: $0.62



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 4
 Employees 4
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Creative Medical Technology Holdings Inc. is a biotechnology company that focuses on developing and commercializing stem cell-based therapies and products to treat various medical conditions. The company's innovative approach involves using stem cells derived from the patient's own adipose tissue to develop personalized treatments. The therapies are aimed at addressing conditions like erectile dysfunction, immune system disorders, and degenerative conditions of the spine, among others. Creative Medical Technology Holdings Inc. aims to bring much-needed advancements in regenerative medicine to improve patient outcomes and quality of life.


   Company Address: 211 E Osborn Road Phoenix 85012 AZ
   Company Phone Number: 399-2822   Stock Exchange / Ticker: NASDAQ CELZ


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BCRX   -7.16%    
IOVA        4.35% 
NVCT        0.78% 
RIGL   -0.44%    
• View Complete Report
   



Product Service News

Medical Technology Holdings Advances in Type 1 Diabetes and AI-Driven Healing Initiatives

Published Thu, Jul 17 2025 3:43 PM UTC

PHOENIX, July 2025 Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology firm focused on regenerative medicine, has announced significant developments in the prevention and treatment of Type 1 Diabetes (T1D) and in the field of AI-driven medical diagnostic programs.On July 17, 2025, the company received a Notice of Allowance from the Unit...
Management Announcement

Revolutionizing Regenerative Medicine: Medical Technology Holdings Leads the Charge in IVF and Chronic Pain Treatments

Published Thu, Feb 20 2025 1:01 PM UTC

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is making waves in the health and wellness sector with its innovative approaches to reproductive health and pain management. The company is garnering attention not only for its pioneering OvaStem program, which enhances access to in vitro fertilization (IVF), but also for its significant advancements in treating chron...
Clinical Study

Innovative Regenerative Approach Medical Technologys Breakthrough in Chronic Lower Back Pain Treatment

Published Wed, Nov 13 2024 2:00 PM UTC

In an exciting advancement for the field of regenerative medicine, Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has announced a significant milestone in its ADAPT clinical trial. As of November 13, 2024, the independent Data Safety Monitoring Board (DSMB) has successfully completed an interim safety review, affirming the safety and potential efficacy of CELZ-201...
Shares

Medical Technology Holdings Announces $1.85 Million Share Offering to Enhance Immunotherapy Initiatives

Published Wed, Oct 23 2024 12:01 PM UTC

In a strategic move to bolster its innovative healthcare initiatives, Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), announced on October 23, 2024, that it has successfully entered into definitive securities purchase agreements with institutional investors for a registered direct offering of common stock. The deal amounts to approximately $1.85 million, with the ...
Product Service News

Medical Technology Holdings Advances AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure

Published Wed, Jul 24 2024 1:01 PM UTC

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), an innovative biotechnology company specializing in regenerative therapies, has recently embarked on a groundbreaking initiative. The company announced the development of an AI-driven diagnostic and treatment program designed to aid patients exposed to biological and chemical weapons. By combining Artificial Intellig...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1,307.92
Price to Sales (Expected) -
Price to Book 0.45
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.36
Working Capital Ratio 12.91
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.06 $
Revenues (TTM) 0 $
Cash Flow (TTM) -
Cash 0.07 $
Book Value 2.34 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,509,644
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.